-
-
-
-
BAFF-R CAR-T: CR 100%
CAR-T
PeproMene Bio's BAFF-R targeted CAR-T therapy PMB-CT01 shows 100% complete response in Phase 1 trials for B-cell lymphomas and leukemia, offering promising, durable results with manageable safety.
-
-
Stylus Medicine Raises $85 Million!
Eli Lilly
Stylus Medicine raises $85M to develop in vivo CAR-T cell therapies, targeting gene insertion, non-viral DNA delivery, and cell therapy solutions with backing from Eli Lilly, Johnson & Johnson, and others.
-
-
2024 Global CAR-T Sales Performance
CAR-T
Discover the sales performance of CAR-T therapies in 2024, including Kymriah, Yescarta, Breyanzi, and more. Explore trends, growth, and challenges in the CAR-T cell therapy market across the US and beyond.
-
In Vivo CAR-T: A New Horizon
CAR-T
Explore the promising future of in vivo CAR-T therapy, a breakthrough in cancer and autoimmune disease treatment. Companies like Interius and Umoja are leading the way with innovative in vivo CAR-T therapies targeting CD19, CD20, and CD22. Discover the latest advances and clinical trials.
垦利县|
麻阳|
瑞昌市|
凌源市|
英吉沙县|
西安市|
贵港市|
高密市|
灵石县|
云安县|
阳曲县|
中山市|
阜城县|
老河口市|
昌江|
天门市|
福海县|
崇明县|
云安县|
和田市|
武冈市|
常宁市|
普宁市|
上林县|
那曲县|
开封市|
杭锦后旗|
高碑店市|
泾川县|
徐闻县|
孙吴县|
宽城|
美姑县|
博爱县|
长汀县|
库伦旗|
白水县|
西充县|
昌黎县|
平邑县|
台山市|